• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Fluocinolone acetonide implant gets German marketing approval

Article

An intravitreal implant that delivers sub-microgram levels of fluocinolone acetonide for up to 36 months (Iluvien, Alimera Sciences Inc.), has been granted marketing authorization by the Federal Ministry of Health of Germany (Bundesministerium fur Gesundheit, BfArM) for the treatment of vision impairment associated with chronic diabetic macular edema considered insufficiently responsive to available therapies.

Atlanta-An intravitreal implant that delivers sub-microgram levels of fluocinolone acetonide for up to 36 months (Iluvien, Alimera Sciences Inc.) has been granted marketing authorization by the Federal Ministry of Health of Germany (Bundesministerium fur Gesundheit, BfArM) for the treatment of vision impairment associated with chronic diabetic macular edema considered insufficiently responsive to available therapies.

This marketing authorization follows the completion of the decentralized regulatory procedure, in which the Medicines and Healthcare Products Regulatory Agency in the United Kingdom, serving as the reference member state, delivered a positive outcome for the implant along with six concerned members states: Austria, France, Germany, Italy, Spain, and Portugal. The German authorization is the fifth national approval in the European Union, preceded by Austria, Portugal, the United Kingdom, and France.

“We are very pleased to receive German marketing authorization for [the fluocinolone acetonide implant], our fifth of seven expected approvals in the European Union,” said Dan Myers, president and chief executive officer, Alimera Sciences. “Assuming the closing of our recently announced financing, we anticipate that we will launch [the implant] in Germany during the first quarter of 2013.”

For more articles in this issue of Ophthalmology Times eReport, click here.

Related Videos
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
Elizabeth Yeu, MD, highlights from a corneal case report for a patient undergoing the triple procedure
William F. Wiley, MD, shares some key takeaways from his ASCRS presentation on binocularity and aperture optics.
© 2024 MJH Life Sciences

All rights reserved.